Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases

Abstract

A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.

1 . A use of an inhalable powder formulation comprising growth hormone (GH) as an active ingredient for preventing or treating an NMDA receptor hypofunction-related disease. 
     
     
         2 . The use of  claim 1 , wherein the NMDA receptor hypofunction-related disease is selected from the group consisting of schizophrenia; schizophrenia-like symptoms including cognitive impairments; Alzheimer's disease; age-related decreases in memory and learning; drug-induced NMDA receptor hypofunction; NMDA antagonist-induced psychotic symptoms or cognitive impairments; huntington disease; and chronic alcoholics. 
     
     
         3 . The use of  claim 1 , wherein the inhalable powder formulation further comprises a pharmaceutically acceptable excipient. 
     
     
         4 . The use of  claim 3 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of monosaccharides such as glucose and arabinose; disaccharides such as lactose, saccharose and maltose; polysaccharides such as sorbitol, mannitol and xylitol; salts such as sodium chloride and calcium carbonate; sodium bicarbonate; amino acids; peptides; polymers; lipids; and a mixture thereof 
     
     
         5 . The use of  claim 1 , wherein the inhalable powder formulation comprises growth hormone, lactose and dipalmitoyl phosphatidylcholine (DPPC). 
     
     
         6 . The use of  claim 5 , wherein the inhalable powder formulation comprises human growth hormone (hGH), lactose and dipalmitoyl phosphatidylcholine (DPPC) in the ratio of 1:0.5-1.5:1-5 by weight. 
     
     
         7 . A method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof. 
     
     
         8 . An inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising growth hormone (GH) as an active ingredient.